home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9604b.zip
/
M9640680.TXT
< prev
next >
Wrap
Text File
|
1996-03-04
|
5KB
|
70 lines
Document 0680
DOCN M9640680
TI Therapy of murine tumors with tumor peptide-pulsed dendritic cells:
dependence on T cells, B7 costimulation, and T helper cell 1-associated
cytokines [see comments]
DT 9604
AU Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT;
Storkus WJ; Department of Surgery, University of Pittsburgh,
Pennsylvania; 15261, USA.
SO J Exp Med. 1996 Jan 1;183(1):87-97. Unique Identifier : AIDSLINE
MED/96136751
CM Comment in: J Exp Med 1996 Jan 1;183(1):7-11
AB Antigen presentation by host dendritic cells (DC) is critical for the
initiation of adaptive immune responses. We have previously demonstrated
in immunogenic murine tumor models that bone marrow (BM)-derived DC
pulsed ex vivo with synthetic tumor-associated peptides, naturally
expressed by tumor cells, serve as effective antitumor vaccines,
protecting animals against an otherwise lethal tumor challenge
(Mayordomo, J.I., T. Zorina, W.J. Storkus, C. Celluzzi, L.D. Falo, C.J.
Melief, T. Ildstad, W.M. Kast, A.B. DeLeo, and M.T. Lotze. 1995. Nature
Med. 1:1297-1302). However, T cell-defined epitopes have not been
identified for most human cancers. To explore the utility of this
approach in the treatment of tumors expressing as yet uncharacterized
epitopes, syngeneic granulocyte/macrophage colony-stimulating
factor-stimulated and BM-derived DC, pulsed with unfractionated
acid-eluted tumor peptides (Storkus, W.J., H.J. Zeh III, R.D. Salter,
and M.T. Lotze. 1993. J. Immunother. 14:94-103) were used to treat mice
bearing spontaneous, established tumors. The adoptive transfer of 5 x
10(5) tumor peptide-pulsed DC dramatically suppressed the growth of
weakly immunogenic tumors in day 4 to day 8 established MCA205 (H-2b)
and TS/A (H-2d) tumor models, when applied in three biweekly intravenous
injections. Using the immunogenic C3 (H-2b) tumor model in B6 mice,
tumor peptide-pulsed DC therapy resulted in the erradication of
established d14 tumors and long-term survival in 100% of treated
animals. The DC-driven antitumor immune response was primarily cell
mediated since the transfer of spleen cells, but not sera, from
immunized mice efficiently protected sublethally irradiated naive mice
against a subsequent tumor challenge. Furthermore, depletion of either
CD4+ or CD8+ T cells from tumor-bearing mice before therapy totally
suppressed the therapeutic efficacy of DC pulsed with tumor-derived
peptides. Costimulation of the host cell-mediated antitumor immunity was
critical since inoculation of the chimeric fusion protein CTLA4-Ig
virtually abrogated the therapeutic effects of peptide-pulsed DC in
vivo. The analysis of the cytokine pattern in the draining lymph nodes
and spleens of tumor-bearing mice immunized with DC pulsed with
tumor-eluted peptides revealed a marked upregulation of interleukin (IL)
4 and interferon (IFN) gamma production, as compared with mice immunized
with DC alone or DC pulsed with irrelevant peptides. DC-induced
antitumor effects were completely blocked by coadministration of
neutralizing monoclonal antibody directed against T helper cell
1-associated cytokines (such as IL-12, tumor necrosis factor alpha,
IFN-gamma), and eventually, but not initially, blocked by anti-mIL-4
mAb. Based on these results, we believe that DC pulsed with acid-eluted
peptides derived from autologous tumors represents a novel approach to
the treatment of established, weakly immunogenic tumors, and serves as a
basis for designing clinical trials in cancer patients.
DE Animal Antigen Presentation Antigens, CD/IMMUNOLOGY
Cytokines/IMMUNOLOGY Dendritic Cells/*IMMUNOLOGY Histocompatibility
Antigens Class I/IMMUNOLOGY *Immunotherapy, Adoptive Lymph
Nodes/IMMUNOLOGY Membrane Glycoproteins/IMMUNOLOGY Mice Mice, Inbred
BALB C Mice, Inbred C57BL Neoplasm Proteins/*IMMUNOLOGY/METABOLISM
Neoplasms, Experimental/*THERAPY Peptides/*IMMUNOLOGY/METABOLISM
Spleen/IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.
T-Lymphocytes, Cytotoxic/IMMUNOLOGY T-Lymphocytes,
Helper-Inducer/IMMUNOLOGY Th1 Cells/IMMUNOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).